You are here

Europe

Pfizer gets green light for Ibrance in EU

Pfizer gets green light for Ibrance in EU

BioPharma Dive

Flag link:

J&J, GSK advance their PhIII IL-6 rheumatoid arthritis drug down to a busy red zone

J&J, GSK advance their PhIII IL-6 rheumatoid arthritis drug down to a busy red zone

Endpoints

rheumatoid arthritis

Flag link:

Drug maker loses appeal of antitrust pay-to-delay case in Europe

Drug maker loses appeal of antitrust pay-to-delay case in Europe

Stat/Pharmalot

antidepressants

Flag link:

Pfizer Gets European Approval For XALKORI, A Cell Lung Cancer Treatment

Pfizer Gets European Approval For XALKORI, A Cell Lung Cancer Treatment

Yahoo/Benzinga

non-small cell lung cancer

Flag link:

Could Pfizer Face An Apple-Like Tax Surprise in the EU?

Could Pfizer Face An Apple-Like Tax Surprise in the EU?

Motley Fool

Flag link:

Gilead Sciences, Inc. to Extend Reach in HIV Drugs Market Via Truvada’s Approval

Gilead Sciences, Inc. to Extend Reach in HIV Drugs Market Via Truvada’s Approval

Bidness, ETC

Gilead Sciences

Flag link:

Merck’s KEYTRUDA® (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1

Merck’s KEYTRUDA® (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1

Yahoo

non-small cell lung cancer

Flag link:

'Sunshine' hits Europe: Pharma's doc payments now available, but numbers are far from comprehensive

'Sunshine' hits Europe: Pharma's doc payments now available, but numbers are far from comprehensive

Fierce Pharma

physician payments

Physician Payment Sunshine Act

Flag link:

Gilead Gets European CHMP's Positive Opinion On Its Type II Variation Application For Truvada

Gilead Gets European CHMP's Positive Opinion On Its Type II Variation Application For Truvada

Yahoo

Gilead Sciences

Flag link:

Mylan gets 'all clear' from EU regulators for $7.2 billion Meda deal

Mylan gets 'all clear' from EU regulators for $7.2 billion Meda deal

BioPharma Dive

Flag link:

New CEO Szela cuts Aegerion staff again, pulls Juxtapid out of the EU

New CEO Szela cuts Aegerion staff again, pulls Juxtapid out of the EU

Endpoints

Aegerion Pharmaceuticals

Flag link:

AZ's FDA-rejected diabetes combo grabs first-to-market status in Europe

AZ's FDA-rejected diabetes combo grabs first-to-market status in Europe

Fierce Pharma

Flag link:

GlaxoSmithKline and AstraZeneca Form Brexit Task Force

GlaxoSmithKline and AstraZeneca Form Brexit Task Force

Xtalks

Flag link:

Gilead secures European approval for new hepatitis C drug

Gilead secures European approval for new hepatitis C drug

BioPharma Dive

Gilead Sciences

Flag link:

Seattle Genetics drug gets OK for additional cancer therapies in Europe

Seattle Genetics drug gets OK for additional cancer therapies in Europe

Bizjournals.com

Seattle Genetics

Hodgkin's lymphoma

Flag link:

Brexit’s Impact on Pharmaceutical Research and Development

Brexit’s Impact on Pharmaceutical Research and Development

Market Realist

Flag link:

Shire and Glaxo Offer Prescription to London's Woes

Shire and Glaxo Offer Prescription to London's Woes

TheStreet.com

Flag link:

UK pharma trade group on Brexit: ‘There’s a potentially negative story here’

UK pharma trade group on Brexit: ‘There’s a potentially negative story here’

Stat

Association of the British Pharmaceutical Industry

Flag link:

GSK, GILD, AZN: How Brexit Affects Drug Stocks

GSK, GILD, AZN: How Brexit Affects Drug Stocks

Bidness, ETC

Gilead Sciences

Flag link:

Brexit Won't Change Britain's Drug Regulatory Scheme

Brexit Won't Change Britain's Drug Regulatory Scheme

Forbes

Flag link: